MT2A and laryngeal carcinoma: Recently, a number of new molecular markers have been found successively, ERCC1 rs11615 and ERCC5 rs17655 polymorphisms [31], genetic variation of MT2A [32], CYP1B1*2 355T and CYP2E1*5-1293C [33] and XPG Asp1104His [34] were reported to be associated with increased risk of laryngeal cancer, while ERp57-STAT3 regulation functions may regulation functions in radioresistance of laryngeal cancer, and targeting the ERp57-STAT3 pathway might be important for enhancing the efficacy of radiotherapy in human laryngeal cancer [35].